Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 47 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:21 de noviembre. [Ref.ID 103194]
2.Enlace a cita original
Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]
3.Enlace a cita original Cita con resumen
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Kefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD, for the PARADIGM-HF Investigators. Influenze of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:1-8. [Ref.ID 100489]
4. Cita con resumen
McMurray JJV, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM, for the ATHMOSPHERE Committees Investigators. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016;374:1521-32. [Ref.ID 100244]
5.Tiene citas relacionadas Cita con resumen
Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret C, Van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, De Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, De Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsley JD, Chasman D, Ridker PM, Magglioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Forhage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hoogeveen A, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61. [Ref.ID 98804]
6.Tiene citas relacionadas Cita con resumen
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin - Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98476]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]
8. Cita con resumen
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98005]
9.Tiene citas relacionadas Cita con resumen
McMurray JJV, Jhund PS. Cardiovascular risks with azithromycin. N Engl J Med 2013;369:579. [Ref.ID 95973]
10. Cita con resumen
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJV, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, for the RED-HF Committees and Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-9. [Ref.ID 95165]
11. Cita con resumen
Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC. Heart fail 2013;1:21-8. [Ref.ID 94659]
12.
Schwartz GG, Olsson AG, Abt M, Mallantyne CM, Barter PJ, Brumm J, Chatman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundi H, Nicholis SJ, Shah PK, Tardif JC, Wright RS, for the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99. [Ref.ID 94165]
13.Tiene citas relacionadas
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Baht MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJV, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomsied controlled trial. Lancet 2012;380:1749-58. [Ref.ID 94073]
14. Cita con resumen
Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJV. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012;308:804-11. [Ref.ID 93611]
15.Tiene citas relacionadas
O'Connor CM, Starling RC, Hernandez AF, Dickstein AK, Hasselblad V, Heizer GM, Massie BM, McMurray JJV, Nieminen MS, Reist CJ, Rouleau RJL, Swedberg K, Adams Jr KF, Battler AA, Botero R, Bohidar NR, Clausell BN, Corbalán NCR, Costanzo MR, Dahlstrom U, Deckelbaum Li, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois FD, Méndez SS, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski PP, Tang WHW, Tanomsup S, Teerlink JR, Triposkjadis F, Troughton RW, Voors AA, Whellan DJ, Zannad WF, Califf RM. Effect of nesiritide in patients with acute decomensated heart failure. N Engl J Med 2011;365:32-43. [Ref.ID 90905]
16.Tiene citas relacionadas
Zannad F, McMurray JJV, Swedberg K. Eplerenone in mild heart failure. Author/editor response. N Engl J Med 2011;364:1372. [Ref.ID 90543]
17.Tiene citas relacionadas Cita con resumen
Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. [Ref.ID 90013]
18.Tiene citas relacionadas Cita con resumen
Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving H-H, Remuzzi G, Singh AK, Solomon SD, Toto R, for the TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32. [Ref.ID 87324]
19.Tiene citas relacionadas Cita con resumen
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV, for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35. [Ref.ID 86100]
20.Tiene citas relacionadas Cita con resumen
Gerstein HC, Swedberg K, Carlsson J, McMurray JJV, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S, for the CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure. Arch Intern Med 2008;168:1699-704. [Ref.ID 83827]
Seleccionar todas
 
 1 a 20 de 47 siguiente >>